Shingles vaccine for 50-somethings

Zostavax, a live attenuated virus vaccine to prevent shingles, has been FDA-approved for people in their 50s.

It was originally approved in 2006 for people 60 and older.

“The likelihood of shingles increases with age.  The availability of Zostavax to a younger age group provides an additional opportunity to prevent this often painful and debilitating disease, “ said Dr. Karen Midthun, director of the FDA’s Center for Biologics Evaluation and Research.

Extending vaccine approval  was based on a  study conducted in the U.S. and four other countries with 22,000 people ages 50-59. Half received Zostavax and half received a placebo. The vaccine was found to reduce the risk of developing shingles by about 70 percent, according to the FDA.

Shingles — characterized by a rash of blisters and pain —  is  caused by the varicella-zoster virus, the same virus that causes chickenpox. After chickenpox,  it remains dormant in the body but can reappear later as shingles, especially due to aging or a weakened immune system.
 
 

Comments

News-Gazette.com embraces discussion of both community and world issues. We welcome you to contribute your ideas, opinions and comments, but we ask that you avoid personal attacks, vulgarity and hate speech. We reserve the right to remove any comment at our discretion, and we will block repeat offenders' accounts. To post comments, you must first be a registered user, and your username will appear with any comment you post. Happy posting.

Login or register to post comments